NCT05020145
- Conditions
- Breakthrough Infection, Breakthrough Infections, COVID-19, +18 more
- Locations
-
- Pfizer Inc. New York, United States
Clinical trial condition
Explore clinical trials studying SARS-CoV-2. Study availability and eligibility vary by location and protocol.
NCT05020145
NCT04516746
NCT05903118
NCT04473365
NCT04866303
NCT04779424
NCT04675281
NCT05077930
NCT04674189
NCT04515147